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ABSTRACT
Bioﬁlm formation in 92 unrelated strains of
Acinetobacter baumannii isolated in a multicentre
cohort study was investigated using a microtitre
plate assay. Fifty-six (63%) isolates formed
bioﬁlm. These isolates were less frequently resis-
tant to imipenem or ciproﬂoxacin than were non-
bioﬁlm-forming isolates (25% vs. 47%, p 0.04; and
66% vs. 94%, p 0.004, respectively). All catheter-
related urinary or bloodstream infections and the
sole case of shunt-related meningitis were caused
by bioﬁlm-forming strains. Multivariate analysis
revealed that treatment in an intensive care unit,
ciproﬂoxacin resistance and isolation from a respi-
ratory sample were associated with non-bioﬁlm-
forming isolates, while previous aminoglycoside
use was associated with bioﬁlm-forming isolates.
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Acinetobacter baumannii is a signiﬁcant worldwide
nosocomial pathogen with a particular ability to
develop antimicrobial resistance and cause noso-
comial outbreaks of infection [1]. This organism
frequently causes infections associated with med-
ical devices, e.g., vascular catheters, cerebrospinal
ﬂuid shunts or Foley catheters [1–3]. Bioﬁlm
formation is a well-known pathogenic mechanism
in such infections [4]. In addition, the environ-
mental survival of some microorganisms may be
facilitated by bioﬁlm formation on abiotic sur-
faces. Little is known concerning bioﬁlm forma-
tion in A. baumannii [5–8]. Therefore, the present
study investigated the frequency of bioﬁlm for-
mation and the associated clinical correlations and
variables for 92 clonally unrelated isolates selected
from among 221 isolates of A. baumannii collected
during the GEIH-Ab 2000 project [2], which was a
multicentre prospective cohort study performed
in 28 Spanish hospitals. The methods and general
clinical, epidemiological and microbiological
results of this study have been reported in detail
elsewhere [2,9,10]. For the purpose of the present
analysis, if an isolate included in this study was
clonally related to at least one other isolate from
the original collection, it was considered to be
epidemic [2]. The study was approved by the local
ethics committees of the participating hospitals.
Bioﬁlm formation was determined in the Hos-
pital Clinic, Barcelona, Spain, using an overnight
culture, diluted 1:100 in fresh Luria–Bertoni broth
in 96-well plates and incubated without shaking at
37C for 48 h. Of the 96 wells, four were left
uninoculated and used as negative controls. Bio-
ﬁlm was stained with crystal violet 1% w ⁄v and
quantiﬁed at 570 nm after solubilisation with
ethanol–acetone. The experiment was performed
in duplicate in two 96-well plates. Isolates were
classiﬁed as bioﬁlm-forming if they yielded OD570
values that were at least twice those of the negative
controls. When an isolate was clearly positive for
bioﬁlm formation in the assay and the duplicate
assaywas borderline, the isolate was considered to
be bioﬁlm-positive. When an isolate was clearly
positive in the ﬁrst assay and the duplicate assay
was clearly negative, the isolate was considered to
be non-evaluable and was excluded. Susceptibility
to antimicrobial agents was determined by micro-
dilution according to CLSI recommendations [11].
The epidemiological and clinical features
of patients colonised or infected with bioﬁlm-
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forming and non-bioﬁlm-forming A. baumannii
isolates were compared. Continuous variables
were compared using the Mann–
Whitney U-test and categorical variables were
compared using the chi-square test (Fisher’s exact
test, if required). Multivariate analysis was
performed by logistic regression analysis.
Statistical analyses were performed using SPSS
v.12.0 (SPSS Inc., Chicago, IL, USA).
Of the 92 isolates studied, 56 (63%) formed
bioﬁlm in vitro, 33 (36%) did not form bioﬁlm,
and three (3%) were non-evaluable. Thus, 89
isolates were used in the ﬁnal analysis. Although
one representative isolate of each pulsed-ﬁeld gel
electrophoresis type was initially analysed, the
results for bioﬁlm formation always agreed with
the representative isolate when other isolates
belonging to the same pulsed-ﬁeld gel electro-
phoresis type from the original collection (‘epi-
demic strains’) were tested. Bioﬁlm-forming
isolates were less frequently imipenem-resistant
(25% vs. 47%, p 0.04), ciproﬂoxacin-resistant
(66% vs. 94%, p 0.004) and epidemic (31% vs.
53%, p 0.04) than were non-bioﬁlm-forming iso-
lates. No signiﬁcant differences in susceptibility
to doxycycline (65% vs. 60%), ceftazidime (73%
vs. 83%), sulbactam (39% vs. 27%), gentamicin
(80% vs. 77%), tobramycin (76% vs. 73%) or
rifampicin (0 vs. 3%) were observed (p >0.1).
Complete epidemiological and clinical data
were available for 78 patients and were included
in the analysis of factors associated with bioﬁlm
formation. Univariate analyses are shown in
Table 1. ORs (95% CI) for the variables selected
in multivariate analysis were: treatment in an
intensive care unit, 0.1 (0.004–0.8); respiratory
tract sample, 0.2 (0.005–0.4); ciproﬂoxacin resis-
tance, 0.06 (0.009–0.4); and previous receipt of
aminoglycosides, 13.1 (2.3–74.9). When CDC cri-
teria were used [12], the frequencies of infection
caused by bioﬁlm-forming and non-bioﬁlm-form-
ing isolates were similar (20 ⁄ 49 (41%) vs. 13 ⁄ 29
(45%), p 0.1). Types of infections are shown in
Table 2. Infections caused by non-bioﬁlm-forming
isolates showed a non-signiﬁcant trend toward
the presence of sepsis and a higher mortality rate
when compared with infections caused by bio-
ﬁlm-forming isolates (92% vs. 70%, p 0.1, and
23% vs. 14%, p 0.6, respectively).
There is very limited information concerning
the ability of A. baumannii to form bioﬁlm [5–7]. In
a collection of clinical isolates of A. baumannii,
Sechi et al. [8] found that 16 (80%) of 20 isolates
formed bioﬁlm, perhaps because of a dominant
A. baumannii clone. In the present study, 63% of
92 clonally unrelated A. baumannii clinical isolates
formed bioﬁlm. Interestingly, all clonally related
isolates shared either an ability or an inability to
form a bioﬁlm, which suggests that this is a clone-
speciﬁc feature and that its expression does not
vary substantially under different conditions;
however, further studies are needed to investigate
this hypothesis.
Table 1. Univariate analysis of factors associated with
bioﬁlm-forming isolates of Acinetobacter baumannii (data







(n = 29) OR (95% CI) p valuea
Mean age, years (SD)b 55 (21) 62 (14) – 0.08c
Male gender 72 78 0.7 (0.2–2.0) 0.5
Underlying disease
Non-fatal 74 62 – 0.5
Ultimately fatal 24 32
Rapidly fatal 4 6
Diabetes mellitus 10 22 0.4 (0.1–1.4) 0.1
Neoplasia 17 28 0.5 (0.1–1.5) 0.2
Chronic pulmonary
disease
15 28 0.5 (0.1–1.5) 0.2
ICU treatment 26 53 0.3 (0.1–0.7) 0.01
Mean days of hospital
stay (SD)
29 (37) 22 (25) – 0.3c
Central venous catheter 58 61 0.8 (0.3–2.2) 0.7
Mechanical ventilation 44 52 0.7 (0.2–1.8) 0.4
Urinary catheter 77 77 0.9 (0.3–2.8) 0.9
Previous antimicrobial
agents
86 84 1.3 (0.3–4.8) 0.7
Aminoglycosides 43 20 3.0 (0.9–10.3) 0.06
Fluoroquinolones 21 10 2.4 (0.5–12.3) 0.2
Cephalosporins 46 27 2.3 (0.8–6.2) 0.09
Carbapenems 13 17 0.7 (0.1–3.2) 0.1
Type of sample
Respiratory tract 25 53 0.3 (0.1–0.8) 0.01
Blood 10 0 – 0.07d
Urine 32 14 3.0 (0.9–10.1) 0.06
Wound 27 27 0.9 (0.3–3.0) 0.8
Others 6 6 0.9 (0.1–8.1) 0.8d
ICU, intensive care unit; SD, standard deviation.
aChi-square test except where speciﬁed.




Table 2. Types of infections caused by bioﬁlm-forming
and non-bioﬁlm-forming isolates of Acinetobacter baumannii




forming (n = 13)
IV catheter-related infection 3 0
Foley-related UTI 6 0
CSF shunt infection 1 0
VA respiratory tract infection 5 8
Non-VA respiratory tract infection 1 0
Skin and soft-tissue infection 4 5
IV, intravascular; UTI, urinary tract infection; CSF, cerebrospinal ﬂuid; VA,
ventilator-associated.
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Although limited by the low number of cases,
the present results suggest that bioﬁlm plays a
role in the pathogenesis of some device-associated
A. baumannii infections (e.g., those involving
Foley catheters, venous catheters and cerebrospi-
nal ﬂuid shunts); in contrast, ventilator-associated
pneumonia was not caused predominantly by
bioﬁlm-forming isolates. These results suggest
the hypothesis that infections caused by bioﬁlm-
forming isolates might be associated with a
diminished frequency of systemic response or
mortality; however, this association was not
statistically signiﬁcant and further studies would
be necessary to investigate this possibility.
Bioﬁlm-forming isolates were less frequently
resistant to imipenem and ciproﬂoxacin, and
seemed to be less epidemic. A possible explana-
tion is that bioﬁlm-forming isolates are not as
dependent as their non-bioﬁlm-forming counter-
parts on antimicrobial resistance and epidemic
characteristics to survive in the hospital environ-
ment. Sechi et al. [8] have previously reported no
relationship between bioﬁlm formation and the
production of PER-1 b-lactamase. However,
patients who had previously received aminogly-
cosides were at an increased risk of being colon-
ised or infected by bioﬁlm-forming A. baumannii.
Previous aminoglycoside use may exert a differ-
ent selection pressure on bioﬁlm formation, irre-
spective of the in-vitro susceptibility.
In summary, >60% of unrelated A. baumannii
isolates from clinical samples formed bioﬁlm, and
these isolates were associated mainly with
device-associated infections. These isolates were
less frequently resistant to imipenem and
ciproﬂoxacin.
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